NASDAQ:NRBO NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free NRBO Stock Alerts $3.83 +0.02 (+0.53%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$3.70▼$3.9350-Day Range$3.02▼$4.6652-Week Range$2.89▼$6.75Volume12,306 shsAverage Volume738,007 shsMarket Capitalization$18.78 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get NeuroBo Pharmaceuticals alerts: Email Address NeuroBo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside161.3% Upside$10.00 Price TargetShort InterestHealthy3.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.89) to ($2.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector695th out of 913 stocksPharmaceutical Preparations Industry325th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingNeuroBo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuroBo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about NeuroBo Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.12% of the float of NeuroBo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNeuroBo Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroBo Pharmaceuticals has recently increased by 74.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroBo Pharmaceuticals does not currently pay a dividend.Dividend GrowthNeuroBo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRBO. Previous Next 2.5 News and Social Media Coverage News SentimentNeuroBo Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NeuroBo Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for NRBO on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of NeuroBo Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions.Read more about NeuroBo Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($4.89) to ($2.28) per share.Price to Book Value per Share RatioNeuroBo Pharmaceuticals has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeuroBo Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsProtect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.Discover these 4 simple steps here >>> About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More NRBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRBO Stock News HeadlinesMay 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 22, 2024 | markets.businessinsider.comNeuroBo Pharma Reveals Positive Pre-clinical Data For DA -1241 In Combination In Liver FibrosisMay 22, 2024 | msn.comNeuroBo says DA-1241, Wegovy combo shows potential in treating MASHMay 22, 2024 | msn.comNeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis SuccessMay 22, 2024 | prnewswire.comNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneMay 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug DevelopmentsMay 9, 2024 | msn.comMaxim Group Initiates Coverage of NeuroBo Pharmaceuticals (NRBO) with Buy RecommendationMay 9, 2024 | investorplace.comNRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024May 9, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 30, 2024 | prnewswire.comNeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneApril 23, 2024 | finance.yahoo.comNRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…April 17, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 17, 2024 | prnewswire.comNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityApril 5, 2024 | morningstar.comNeuroBo Pharmaceuticals Inc NRBOApril 1, 2024 | prnewswire.comNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 28, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | prnewswire.comNeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | markets.businessinsider.comNeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8%March 13, 2024 | prnewswire.comNeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHMarch 4, 2024 | finanznachrichten.deNeuroBo Pharmaceuticals, Inc.: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerMarch 4, 2024 | msn.comNeuroBo Pharmaceuticals appoints Marshall Woodworth as CFOMarch 4, 2024 | markets.businessinsider.comNeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFOMarch 4, 2024 | finance.yahoo.comNeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerFebruary 29, 2024 | markets.businessinsider.comNeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock GainsSee More Headlines Receive NRBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/17/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRBO CUSIPN/A CIK1638287 Webwww.neurobopharma.com Phone(857) 702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+161.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.22% Return on Assets-69.52% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book1.11Miscellaneous Outstanding Shares4,906,000Free Float4,880,000Market Cap$18.79 million OptionableNot Optionable Beta-0.30 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Hyung-Heon Kim (Age 49)CEO, President, Principal Executive & Director Comp: $625.16kMr. Marshall H. Woodworth (Age 66)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $154.5kDr. Mi-Kyung KimChief Scientific OfficerMr. Robert HomolkaSenior Vice President of Clinical OperationsKey CompetitorsOncolytics BiotechNASDAQ:ONCYEupraxia PharmaceuticalsNASDAQ:EPRXMilestone PharmaceuticalsNASDAQ:MISTAnnovis BioNYSE:ANVSVaccitechNASDAQ:VACCView All Competitors NRBO Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroBo Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRBO shares. View NRBO analyst ratings or view top-rated stocks. What is NeuroBo Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' shares. Their NRBO share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 161.3% from the stock's current price. View analysts price targets for NRBO or view top-rated stocks among Wall Street analysts. How have NRBO shares performed in 2024? NeuroBo Pharmaceuticals' stock was trading at $3.70 at the start of the year. Since then, NRBO stock has increased by 3.4% and is now trading at $3.8272. View the best growth stocks for 2024 here. Are investors shorting NeuroBo Pharmaceuticals? NeuroBo Pharmaceuticals saw a increase in short interest in May. As of May 31st, there was short interest totaling 62,800 shares, an increase of 74.9% from the May 15th total of 35,900 shares. Based on an average trading volume of 43,500 shares, the short-interest ratio is presently 1.4 days. Approximately 3.1% of the shares of the company are short sold. View NeuroBo Pharmaceuticals' Short Interest. When is NeuroBo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our NRBO earnings forecast. How were NeuroBo Pharmaceuticals' earnings last quarter? NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) issued its earnings results on Thursday, May, 9th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.37. When did NeuroBo Pharmaceuticals' stock split? NeuroBo Pharmaceuticals's stock reverse split on Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of NeuroBo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). How do I buy shares of NeuroBo Pharmaceuticals? Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRBO) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.